SGB 3403
Alternative Names: SGB-3403Latest Information Update: 11 Oct 2023
At a glance
- Originator SanegeneBio
- Class Amides; Amino sugars; Antihyperlipidaemics; Drug conjugates; Small interfering RNA
- Mechanism of Action PCSK9 protein expression modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hypercholesterolaemia
Most Recent Events
- 10 Oct 2023 China Center for Drug Evaluation (CDE) grants clinical trial application approval for SGB 3403 in hypercholesterolemia
- 10 Oct 2023 Pharmacodynamics data from a preclinical trial in Hypercholesterolemia released by SanegeneBio
- 31 May 2023 Phase-I clinical trials in Hypercholesterolaemia (In volunteers) in Australia (SC)